Roche, a prominent pharmaceutical company, has teamed up with Seaside Therapeutics, a small company based in Massachusetts, to release drugs for the treatment of autism spectrum disorders and fragile X syndrome, a rare genetic disease with symptoms similar to autism. The companies attest that the drugs they are developing target the molecular basis and, as a result, the core symptoms of these neuro-developmental disorders.
The drug will act by blocking mGluR5, a brain receptor implicated in both fragile X and autism. Another drug which is still in clinical trials, arbaclofen, which acts by a different mechanism... READ MORE >>
The drug will act by blocking mGluR5, a brain receptor implicated in both fragile X and autism. Another drug which is still in clinical trials, arbaclofen, which acts by a different mechanism... READ MORE >>